Articles tagged "Liver transplantation"

2020 American Transplant Congress
Humanized Mouse Reveals the Cytoprotective Function of Hepatocyte RXFP1 in Liver Transplant Recipients
H. Kojima¹, S. Kageyama¹, K. Kadono¹, H. Hirao¹, K. J. Dery¹, T. Ito¹, G. Sugahara², Y. Ishida², T. Saito², F. M. Kaldas¹, R. W. Busuttil¹, J. W. Kupiec-Weglinski¹
¹Surgery, The Dumont-UCLA Transplantation Center, Los Angeles, CA, ²Division of Gastrointestinal and Liver Disease, Keck School of Medicine, USC, Los Angeles, CA
*Purpose: RXFP1 (RLX family peptide receptor 1) is a cognate receptor for relaxin (RLX), an insulin-like growth factor, with vasoactive/remodeling properties. We have documented cytoprotective…
2020 American Transplant Congress
Results of a Prospective Pilot Program for Transplantation of Patients with Alcohol-Related Liver Disease and Less Than 6 Months Abstinence
J. Quance, L. Carrique, I. Sales, L. Lilly, M. Bhat, Z. Galvin, A. Tan, S. Abbey, J. Lynch, N. Selzner
Multiorgan Transplant Institute, University of Toronto, Toronto, ON, Canada
*Purpose: In Canada, 6 months of abstinence for those with alcohol-associated liver disease (ALD) is typically required prior to being listed for liver transplantation (LT).This…
2020 American Transplant Congress
Outcomes in Liver Transplantation with Use of Granulocyte-Colony Stimulating Factor
K. Schnelle, A. Leino, M. Chunduru, L. Von Stein, O. Witkowsky
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Questions remain if treatment with a granulocyte-colony stimulating factor (G-CSF) impacts clinical outcomes after liver transplant. The purpose of this study was to compare…
2020 American Transplant Congress
Taking Liver Transplant to “The Friendly Skies”: A Novel Pilot Program Using Commercial Flights and Ride-Sharing Apps to Minimize Dry-Run Expenses and Expand Potential Donors
G. J. McKenna, N. Onaca, H. Fernandez, E. Martinez, A. Gupta, A. Wall, J. Bayer, R. Ruiz, G. Testa
Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
*Purpose: Growth in liver transplantation means using marginal/DCD donors, however these often fail to yield a suitable organ. Organ procurement can require travelling significant distances,…
2020 American Transplant Congress
Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma
O. Rizzo, T. Kitajima, M. Kavousi, S. Yeddula, M. Rizzari, K. Collins, A. Yoshida, M. S. Abouljoud, S. Nagai
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Yttrium-90 microspheres radioembolization (Y90) has shown to be effective as a bridging therapy for patients with advanced hepatocellular carcinoma (HCC) while on waiting list…
2020 American Transplant Congress
Early versus Delayed Initiation of CMV Prophylaxis after Liver Transplantation
M. Magid, J. Byrns, J. Gommer, Z. Yang, M. Harris
Duke University Hospital, Durham, NC
*Purpose: To determine the incidence of CMV DNAemia in early (prior to post-op day 7) versus delayed prophylaxis in liver transplant recipients.*Methods: Retrospective, single-center study…
2020 American Transplant Congress
Novel Flow-Based Assay to Detect Allospecific T Cells in Transplantation Study
N. Tanimine¹, B. E. Burrel², J. Pardo², C. Rickert³, K. M. Lee³, K. Deng³, N. Feeney³, C. Leguern³, J. F. Markmann³
¹Department of Gastroenterological and Transplantation Surgery, Hiroshima University, Hiroshima, Japan, ²Immune Tolerance Network, Bethesda, MD, ³Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Identifying and phenotyping donor-reactive T cells in recipients following transplantation may further the understanding of interactions between the recipient’s immune system and donor antigen.…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
T. Kitajima¹, D. Moonka², S. Yeddula¹, M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹, S. Nagai¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…
2020 American Transplant Congress
Barriers to Organ Transplantation among Underrepresented Racial and Ethnic Groups
M. Parra
Duke Clinical Research Institute, Durham, NC
*Purpose: To understand how known patient, provider, and system-level barriers to organ transplantation differ by race and ethnicity.*Methods: We searched Pubmed and Scopus for articles…